cannabidiol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5288	13956-29-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cannabidiol GWP42003-P epidiolex	The precise mechanisms by which cannabidiol exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors. Molecular weight: 314.47 Formula: C21H30O2 CLOGP: LIPINSKI: None HAC: 2 HDO: 2 TPSA: 40.46 ALOGS: ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cannabidiol
GWP42003-P
epidiolex

The precise mechanisms by which cannabidiol exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.

Molecular weight: 314.47
Formula: C21H30O2
CLOGP:
LIPINSKI: None
HAC: 2
HDO: 2
TPSA: 40.46
ALOGS:
ROTB: 6

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	6.69 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	13.55 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	23.82 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 19, 2019	EMA	GW Pharma (International) B.V.
June 25, 2018	FDA	GW RESEARCH LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Device related thrombosis	105.43	23.20	23	3289	1204	46681546
Nail disorder	59.38	23.20	22	3290	7874	46674876
Large intestine polyp	55.82	23.20	21	3291	7840	46674910
Multiple-drug resistance	51.40	23.20	15	3297	2550	46680200
Blood pressure diastolic decreased	46.90	23.20	22	3290	14189	46668561
Drug resistance	45.62	23.20	23	3289	17345	46665405
Body temperature decreased	45.00	23.20	21	3291	13388	46669362
Heart rate irregular	41.30	23.20	22	3290	18569	46664181
Urine leukocyte esterase positive	38.61	23.20	12	3300	2523	46680227
Tonic convulsion	38.57	23.20	10	3302	1096	46681654
Skin exfoliation	36.67	23.20	25	3287	32913	46649837
Therapeutic product effective for unapproved indication	35.94	23.20	6	3306	72	46682678
Blood pressure systolic increased	34.80	23.20	23	3289	28764	46653986
Diarrhoea	33.59	23.20	101	3211	559501	46123249
Drug interaction	33.33	23.20	55	3257	203039	46479711
Urine abnormality	32.78	23.20	13	3299	5581	46677169
Hip fracture	31.57	23.20	21	3291	26535	46656215
Infusion site scar	30.07	23.20	6	3306	202	46682548
Therapeutic product ineffective for unapproved indication	30.07	23.20	6	3306	202	46682548
Breast cancer metastatic	29.85	23.20	16	3296	13662	46669088
Metastases to liver	29.54	23.20	18	3294	19567	46663183
Tri-iodothyronine free decreased	29.34	23.20	6	3306	229	46682521
Metastases to bone	28.79	23.20	17	3295	17459	46665291
Drug level increased	27.94	23.20	17	3295	18424	46664326
Creatinine urine decreased	25.24	23.20	5	3307	162	46682588
Productive cough	25.21	23.20	24	3288	50691	46632059
Wheezing	24.16	23.20	24	3288	53362	46629388

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	64.89	32.30	63	1411	199505	29751499
Seizure	58.44	32.30	44	1430	98431	29852573
Social avoidant behaviour	37.12	32.30	11	1463	2852	29948152
Behaviour disorder	34.49	32.30	10	1464	2402	29948602
Alcohol intolerance	33.49	32.30	7	1467	433	29950571

Pharmacologic Action:

Source	Code	Description
ATC	N03AX24	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics
FDA CS	M0003267	Cannabinoids
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
FDA MoA	N0000182138	Cytochrome P450 1A2 Inhibitors
FDA MoA	N0000182139	Cytochrome P450 2B6 Inhibitors
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000185504	Cytochrome P450 2C9 Inhibitors
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors
FDA MoA	N0000187064	Cytochrome P450 2B6 Inducers
FDA MoA	N0000191273	UGT2B7 Inhibitors
FDA MoA	N0000191278	UGT1A9 Inhibitors
CHEBI has role	CHEBI:76924	plant metabolites

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Lennox-Gastaut syndrome	indication	230418006
Severe myoclonic epilepsy in infancy	indication	230437002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.34	acidic
pKa2	11.34	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	July 31, 2023	NEW PATIENT POPULATION
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	Sept. 28, 2023	NEW CHEMICAL ENTITY
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	Sept. 28, 2025	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	July 31, 2027	TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	July 31, 2027	TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
G-protein coupled receptor 55	GPCR	Q9Y2T6	GPR55_HUMAN	ANTAGONIST				UNKNOWN	SCIENTIFIC LITERATURE
Transient receptor potential cation channel subfamily V member 1	Ion channel	Q8NER1	TRPV1_HUMAN	INHIBITOR				UNKNOWN	SCIENTIFIC LITERATURE

External reference:

ID	Source
4036658	VANDF
C0006863	UMLSCUI
CHEBI:69478	CHEBI
P0T	PDB_CHEM_ID
CHEMBL190461	ChEMBL_ID
DB09061	DRUGBANK_ID
D002185	MESH_DESCRIPTOR_UI
D10915	KEGG_DRUG
10423	INN_ID
644019	PUBCHEM_CID
4150	IUPHAR_LIGAND_ID
C000628684	MESH_SUPPLEMENTAL_RECORD_UI
19GBJ60SN5	UNII
2045371	RXNORM
20468	MMSL
291103	MMSL
d08919	MMSL
010751	NDDF
771981005	SNOMEDCT_US
96223000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Epidiolex	HUMAN PRESCRIPTION DRUG LABEL	1	70127-100	SOLUTION	100 mg	ORAL	NDA	31 sections
NanoCDB	HUMAN OTC DRUG LABEL	1	70658-122	SOLUTION/ DROPS	1.94 g	BUCCAL	Export only	8 sections
leafPro CBDmed Oil FS QP 3%	HUMAN OTC DRUG LABEL	1	73674-001	OIL	3 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil FS QP 5%	HUMAN OTC DRUG LABEL	1	73674-002	OIL	5 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil FS QP 20%	HUMAN OTC DRUG LABEL	1	73674-005	OIL	20 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil T-FS QD 3%	HUMAN OTC DRUG LABEL	1	73674-020	OIL	3 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil T-FS QD 5%	HUMAN OTC DRUG LABEL	1	73674-021	OIL	5 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil T-FS QD 20%	HUMAN OTC DRUG LABEL	1	73674-024	OIL	20 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Softgels FS QP 20	HUMAN OTC DRUG LABEL	1	73674-052	CAPSULE, LIQUID FILLED	20 mg	ORAL	unapproved drug other	15 sections
leafPro CBDmed Softgels T-FS QD 20	HUMAN OTC DRUG LABEL	1	73674-061	CAPSULE, LIQUID FILLED	20 mg	ORAL	unapproved drug other	15 sections
Kaydia Patch	HUMAN OTC DRUG LABEL	3	75140-002	PATCH	0.15 g	TOPICAL	unapproved drug other	8 sections